


PHARMACEUTICAL 2019



CNBX Pharmaceuticals Inc. Rank 225 of 363





PHARMACEUTICAL 2019



CNBX Pharmaceuticals Inc. Rank 225 of 363

The relative strengths and weaknesses of CNBX Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CNBX Pharmaceuticals Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 84% points. The greatest weakness of CNBX Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 111% points.

The company's Economic Capital Ratio, given in the ranking table, is 42%, being 4.7% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	1,621
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	539
Liabilities, Non-Current	0
Other Assets	590
Other Compr. Net Income	0
Other Expenses	422
Other Liabilities	0
Other Net Income	32
Other Revenues	9.6
Property and Equipment	974
Research and Development	1,004
Selling, General and Administrative Expense	2,392

Output Variable	Value in 1000 USD
Assets	3,185
Liabilities	539
Expenses	3,818
Revenues	9.6
Stockholders Equity	2,646
Net Income	-3,777
Comprehensive Net Income	-3,777
Economic Capital Ratio	42%

